Showing 3181-3190 of 10618 results for "".
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/attr-cm-trial-acoramidis-long-term/49034/New data from the ATTRibute-CM trial offer insights into the long-term use of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). To learn more about these results and their implications for patient care, Ryan Quigley sits down with Dr. Kevin Alexander, an Assistant ProfessoHow AI Is Transforming Biomarker Development in GI Oncology
https://reachmd.com/programs/project-oncology/ai-biomarker-development-gi-oncology/49169/From tumor detection to biomarker development, artificial intelligence (AI) is rapidly reshaping the landscape of gastrointestinal oncology. In this expert-led program, Dr. William Hall explains how AI is being applied to data to identify tumor features and treatment susceptibilities faster and moreModern Approaches to Long-Term Metastatic Breast Cancer Care
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/long-term-metastatic-breast-cancer-care/48712/Advances in systemic therapies have transformed metastatic breast cancer into a long-term, treatable condition for many patients. Learn more as Dr. Charles Turck sits down with Dr. Adam Brufsky to discuss how we can support these patients by prioritizing quality of life, addressing long-term toxicitAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
https://reachmd.com/programs/neurofrontiers/aducanumab-in-early-alzheimers-slowing-cognitive-and-functional-decline/40002/Aducanumab has historically been a topic of debate in Alzheimer’s treatment, but new data from the EMERGE trial offers further clarity on this anti-amyloid antibody. A detailed analysis of item-level data reveals that high-dose aducanumab slowed disease progression across multiple clinical domains—iNext Steps in COPD Care: Exploring Biologics for Frequent Exacerbators
https://reachmd.com/programs/deep-breaths-updates-chest/next-steps-in-copd-care-exploring-biologics-for-frequent-exacerbators/35933/Despite triple inhaled therapy, many patients with chronic obstructive pulmonary disease (COPD) continue to experience frequent and severe exacerbations, leading to hospitalizations, symptom burden, and higher mortality risk. In this expert-led discussion, Drs. Diego Maselli and Stephanie ChristensoPersonalizing Care for Large Cell Neuroendocrine Carcinoma
https://reachmd.com/programs/project-oncology/personalizing-care-for-large-cell-neuroendocrine-carcinoma/36458/Treatment for large cell neuroendocrine carcinoma often mirrors small cell protocols, but emerging molecular subtypes are reshaping this approach. Learn how next-generation sequencing, biology, and patient-centered decision-making are advancing individualized therapy with Dr. Junaid Arshad, AssistanAll Things Psoriasis With Dr. April Armstrong
https://reachmd.com/series/the-practical-dermatology-podcast/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
https://reachmd.com/programs/neurofrontiers/vorasidenib-and-midh-gliomas-reviewing-the-efficacy-data/32785/Learn about the first targeted treatment for mutant isocitrate dehydrogenase gliomas.Understanding the Cellular Basis for Altered Cognition in Schizophrenia
https://reachmd.com/programs/neurofrontiers/understanding-the-cellular-basis-for-altered-cognition-in-schizophrenia/17873/What’s the significance of somatostatin messenger RNA levels in the dorsolateral prefrontal cortex in schizophrenia? Tune in to find out.Diving into Drug-Induced Liver Injury: What We Need to Know
https://reachmd.com/programs/gi-insights/diving-into-drug-induced-liver-injury-what-we-need-to-know/13072/Drug-induced liver injury continues to be one of the leading causes of acute liver failure. Here’s how you can spot it early on.